PURPOSE: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. METHODS: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. RESULTS: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P < 0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifth-line. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first- to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. CONCLUSIONS: Clinical trials may be feasible in second- or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.
PURPOSE: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. METHODS: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. RESULTS: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P < 0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifth-line. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first- to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. CONCLUSIONS: Clinical trials may be feasible in second- or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.
Authors: Vincent T Janmaat; Ewout W Steyerberg; Ate van der Gaast; Ron Hj Mathijssen; Marco J Bruno; Maikel P Peppelenbosch; Ernst J Kuipers; Manon Cw Spaander Journal: Cochrane Database Syst Rev Date: 2017-11-28
Authors: Hyun Jeong Shim; Ju Young Yun; Jun Eul Hwang; Woo Kyun Bae; Sang Hee Cho; Ik Joo Chung Journal: Gastric Cancer Date: 2011-03-23 Impact factor: 7.370
Authors: Katrine R Schoennemann; Jon K Bjerregaard; Tine P Hansen; Karin De Stricker; Morten F Gjerstorff; Helle A Jensen; Lene W Vestermark; Per Pfeiffer Journal: Gastric Cancer Date: 2011-03-17 Impact factor: 7.370
Authors: John Syrios; Stavros Sougioultzis; Ioannis D Xynos; Nikolaos Kavantzas; Christos Kosmas; George Agrogiannis; John Griniatsos; Ioannis Karavokyros; Emmanouil Pikoulis; Efstratios S Patsouris; Nikolas Tsavaris Journal: BMC Cancer Date: 2012-06-21 Impact factor: 4.430
Authors: Min Jeong Lee; In Gyu Hwang; Joung-Soon Jang; Jin Hwa Choi; Byeong-Bae Park; Myung Hee Chang; Seung Tae Kim; Se Hoon Park; Myoung Hee Kang; Jung Hun Kang Journal: Cancer Res Treat Date: 2012-12-31 Impact factor: 4.679